Recombinant AAV-mediated gene delivery to the central nervous system

Journal of Gene Medicine

Volumn 6, Issue SUPPL. 1, 2004, Pages

  Tenenbaum, L ^a   Chtarto, A ^a   Lehtonen, E ^a   Velu, T ^a   Brotchi, J ^a   Levivier, M ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

AAV; Enzyme replacement; Excitability; Neurological disorders; Neuroprotection

Indexed keywords

ASPARTOACYLASE; BETA ACTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CAPSID PROTEIN; CARBOXYLYASE; DOXYCYCLINE; GALANIN; GENE PRODUCT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE DECARBOXYLASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE GROWTH FACTOR; NEURON SPECIFIC ENOLASE; NEUROPEPTIDE; NEUROTRANSMITTER; NEUROTROPHIC FACTOR; PARVOVIRUS VECTOR; SOMATOMEDIN; TYROSINE 3 MONOOXYGENASE; VIRUS ANTIBODY; ENZYME;

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN INFECTION; CANAVAN DISEASE; CENTRAL NERVOUS SYSTEM; CORPUS STRIATUM; DRUG MECHANISM; DRUG MEGADOSE; ENZYME REPLACEMENT; EPENDYMA CELL; EPILEPSY; GENE EXPRESSION; GENE TRANSFER; GLIA CELL; HUMAN; HUNTINGTON CHOREA; ISCHEMIA; LYSOSOME STORAGE DISEASE; NERVE CELL; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SEROTYPE; SPINAL CORD INJURY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS RECOMBINANT; ADENO ASSOCIATED VIRUS; ANIMAL; BRAIN; GENE VECTOR; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GENETICS; METABOLISM;

ADENO-ASSOCIATED VIRUS; ANIMALIA; CYTOMEGALOVIRUS; GALLUS GALLUS; MIRIDAE;

ANIMALS; BRAIN; DEPENDOVIRUS; ENZYMES; GENETIC ENGINEERING; GENETIC VECTORS; NERVOUS SYSTEM DISEASES; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 4344702714     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.506     Document Type: Review

References (89)

1. McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 1996; 713: 99-107.
2. Klein RL, Meyer EM, Peel AL, et al. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol 1998; 150 183-194.
3. Davidson BL, Stein CS, Heth JA, et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 2000; 97: 3428-3432.
4. Wang C, Wang CM, Clark KR, Sferra TJ. Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain. Gene Ther 2003; 10: 1528-1534.
5. Peel AL, Zolotukhin S, Schrimsher GW, Muzyczka N, Reier PJ. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type- specific promoters. Gene Ther 1997; 4: 16-24.
6. Lo WD, Qu G, Sferra TJ, Clark R, Chen R, Johnson PR. Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum Gene Ther 1999; 10: 201-213.
7. Mastakov MY, Baer K, Symes CW, Leichtlein CB, Kotin RM, During MJ. Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J Virol 2002; 76: 8446-8454.
8. Elliger SS, Elliger CA, Lang C, Watson GL. Enhanced secretion and uptake of beta-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice. Mol Ther 2002; 5: 617-626.
9. Skorupa AF, Fisher KJ, Wilson JM, Parente MK, Wolfe JH. Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp Neurol 1999; 160: 17-27.
10. Bosch A, Perret E, Desmaris N, Heard JM. Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol Ther 2000; 1 63-70.
11. Fu H, Samulski RJ, McCown TJ, Picornell YJ, Fletcher D, Muenzer J. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Mol Ther 2002; 5: 42-49.
12. Leone P, Janson CG, Bilaniuk L, et al. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol 2000; 48: 27-38.
13. Matalon R, Surendran S, Rady PL, et al. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for Canavan disease. Mol Ther 2003; 7: 580-587.
14. Janson C, McPhee S, Bilaniuk L, et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 2002; 13: 1391-1412.
15. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994; 8: 148-154.
16. During MJ, Samulski RJ, Elsworth JD, et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther 1998; 5: 820-827.
17. Leff SE, Spratt SK, Snyder RO, Mandel RJ. Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease. Neuroscience 1999; 92: 185-196.
18. Fan DS, Ogawa M, Fujimoto KI, et al. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum Gene Ther 1998; 9: 2527-2535.
19. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000; 20: 4686-4700.
20. McBride JL, During MJ, Wuu J, Chen EY, Leurgans SE, Kordower JH. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol 2003; 182: 213-223.
21. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003; 301: 839-842.
22. Klein RL, Hirko AC, Meyers CA, Grimes JR, Muzyczka N, Meyer EM. NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res 2000; 875: 144-151.
23. Tsai TH, Chen SL, Chiang YH, et al. Recombinant adeno-associated virus vector expressing glial cell line-derived neurotrophic factor reduces ischemia-induced damage. Exp Neurol 2000; 166: 266-275.
24. Blits B, Oudega M, Boer GJ, Bartlett Bunge M, Verhaagen J. Adeno-associated viral vector-mediated neurotrophin gene transfer in the injured adult rat spinal cord improves hind-limb function. Neuroscience 2003; 118: 271-281.
25. Haberman RP, McCown TJ, Samulski RJ. Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med 2003; 9: 1076-1080.
26. Haberman RP, McCown TJ, Samulski RJ. Therapeutic liabilities of in vivo viral vector tropism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity. Mol Ther 2002; 6: 495-500.
27. Peel AL, Klein RL. Adeno-associated virus vectors: activity and applications in the CNS. J Neurosci Methods 2000; 98: 95-104.
28. Lehtonen E, Tenenbaum L. Adeno-associated viral vectors. Int Rev Neurobiol 2003; 55: 65-98.
29. Mandel RJ, Rendahl KG, Snyder RO, Leff SE. Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors. Exp Neurol 1999; 159: 47-64.
30. Bosch A, Heard JM. Gene therapy for mucopolysaccharidosis. Int Rev Neurobiol 2003; 55: 271-296.
31. Muramatsu S, Wang L, Ikeguchi K, et al. Adeno-associated viral vectors for Parkinson's disease. Int Rev Neurobiol 2003; 55: 205-222.
32. Leone P, Janson CG, McPhee SJ, During MJ. Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease. Curr Opin Mol Ther 1999; 1: 487-492.
33. Björklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 2000; 88: 82-98.
34. Tenenbaum L, Jurysta F, Stathopoulos A, et al. Tropism of AAV-2 vectors for neurons of the globus pallidus. NeuroReport 2000; 11: 2277-2283.
35. Xiao X, McCown TJ, Li J, Breese GR, Morrow AL, Samulski RJ. Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res 1997; 756: 76-83.
36. Hermens WT, ter Brake O, Dijkhuizen PA, et al. Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum Gene Ther 1999; 10: 1885-1891.
37. Luo J, Kaplitt MG, Fitzsimons HL, et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 2002; 298: 425-429.
38. Nguyen JB, Sanchez-Pernaute R, Cunningham J, Bankiewicz KS. Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain. NeuroReport 2001; 12: 1961-1964.
39. Mastakov MY, Baer K, Kotin RM, During MJ. Recombinant adeno-associated virus serotypes 2- and 5-mediated gene transfer in the mammalian brain: quantitative analysis of heparin co-infusion. Mol Ther 2002; 5: 371-380.
40. Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000; 164: 12-14.
41. Klein RL, Lewis MH, Muzyczka N, Meyer EM. Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res 1999; 847: 314-320.
42. Prösch S, Stein J, Staak K, et al. Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biol Chem Hoppe-Seyler 1996; 377: 195-201.
43. Xu R, Janson CG, Mastakov M, et al. Quantitative comparison of expression with adeno-associated virus(AAV-2) brain-specific gene cassettes. Gene Ther 2001; 8: 1323-1332.
44. Klein RL, Hamby ME, Gong Y, et al. Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp Neurol 2002; 176: 66-74.
45. Loeb JE, Cordier WS, Harris ME, Weitzman MD, Hope TJ. Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy. Hum Gene Ther 1999; 10 2295-2305.
46. Paterna JC, Moccetti T, Mura A, Feldon J, Büeler H. influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Ther 2000; 7: 1304-1311.
47. Wu P, Phillips MI, Bui J, Terwilliger EF. Adeno-associated virus vector-mediated transgene integration into neurons and other nondividing cell targets. J Virol 1998; 72: 5919-5926.
48. Schnepp BC, Clark KR, Elemanski DL, Pacak CA, Johnson PR. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 2003; 77: 3495-3504.
49. Afione SA, Conrad CK, Kearns WG, et al. In vivo model of adeno-associated virus vector persistence and rescue. J Virol 1996; 70: 3235-3241.
50. Bartlett JS, Samulski RJ, McCown TJ. Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther 1998; 9: 1181-1186.
51. Keir SD, Miller J, Yu G, et al. Efficient gene transfer into primary and immortalized human fetal glial cells using adeno-associated virus vectors: establishment of a glial cell line with a functional CD4 receptor. J Neurovirol 1997; 3: 322-330.
52. Tenenbaum L, Darling JL, Hooghe-Peters E. Adeno-associated virus (AAV) as a vector for gene transfer into glial cells of the human central nervous system. Gene Ther 1994; 1: S80.
53. Chtarto A, Bender HU, Hanemann CO, et al. Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Ther 2003; 10: 86-96.
54. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445.
55. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999; 5: 71-77.
56. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5: 78-82.
57. Fuxe K, Chadi G, Tinner B, Agnati LF, Pettersson R, David G. On the regional distribution of heparan sulfate proteoglycan immunoreactivity in the rat brain. Brain Res 1994; 636: 131-138.
58. Matsuo A, Tooyama I, Isobe S, et al. Immunohistochemical localization in the rat brain of an epitope corresponding to the fibroblast growth factor receptor-1. Neuroscience 1994; 60: 49-66.
59. Flotte TR, Afione SA, Solow R, et al. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem 1993; 268: 3781-3790.
60. Haberman RP, McCown TJ, Samulski RJ. Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J Virol 2000; 74: 8732-8739.
61. Chen H, McCarty DM, Bruce AT, Suzuki K. Gene transfer and expression in oligodendrocytes under the control of myelin basic protein transcriptional control region mediated by adeno-associated virus. Gene Ther 1998; 5: 50-58.
62. Chen H, McCarty DM, Bruce AT, Suzuki K. Oligodendrocyte-specific gene expression in mouse brain: use of a myelin-forming cell type-specific promoter in an adeno-associated virus. J Neurosci Res 1999; 55: 504-513.
63. Eng LF, Ghinikar RS, Lee YL. Glial fibrillary acidic protein: GFAP: thirty-one years (1969-2000). Neurochem Res 2000; 5: 1439-1451.
64. Byrnes AP, Rusby JE, Wood MJ, Charlton HM. Adenovirus gene transfer causes inflammation in the brain. Neuroscience 1995; 66 1015-1024.
65. Hermens WT, Verhaagen J. Adenoviral vector-mediated gene expression in the nervous system of immunocompetent Wistar and T cell-deficient nude rats: preferential survival of transduced astroglial cells in nude rats. Hum Gene Ther 1997; 8: 1049-1063.
66. Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791-801.
67. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 2001; 75: 6884-6893.
68. Walters RW, Yi SM, Keshavjee S, et al. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 2001; 276: 20 610-20 616.
69. Pasquale GD, Davidson BL, Stein CS, et al. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 2003; 9: 1306-1312.
70. Tenenbaum L, Chtarto A, Lehtonen E, et al. Neuroprotective gene therapy for Parkinson's disease. Curr Gene Ther 2002; 2: 451-483.
71. Hefti F, Melamed E, Sahakian BJ, Wurtman RJ. Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA. Pharmacol Biochem Behav 1980; 12: 185-188.
72. Mandel RJ, Spratt SK, Snyder RO, Leff SE. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci U S A 1997; 94: 14 083-10 488.
73. Wang LJ, Lu YY, Muramatsu S, et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci 2002; 22: 6920-6928.
74. Eaton MJ, Blits B, Ruitenberg MJ, Verhaagen J, Oudega M. Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord. Gene Ther 2002; 9: 1387-1395.
75. Lindvall O, Widner H, Rehncrona S, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 1992; 31: 155-165.
76. Lehtonen E, Bonnaud F, Melas C, et al. Recombinant AAV2 vector mediates efficient and sustained transduction of rat and human embryonic ventral mesencephalon. NeuroReport 2002; 13: 1503-1507.
77. Piccini P, Brooks DJ, Bjorklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999; 2: 1137-1140.
78. Wu P, Ye Y, Svendsen CN. Transduction of human neural progenitor cells using recombinant adeno-associated viral vectors. Gene Ther 2002; 9: 245-255.
79. Zapata A, Capdevila JL, Tarrason G, et al. Effects of NMDA-R1 antisense oligodeoxynucleotide administration: behavioral and radioligand binding studies. Brain Res 1997; 745: 114-120.
80. Georgievska B, Kirik D, Björklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 2002; 177: 461-477.
81. Haberman RP, McCown TJ. Regulation of gene expression in adeno-associated virus vectors in the brain. Methods 2002; 28 219-226.
82. Oligino T, Poliani PL, Wang Y, et al. Drug inducible transgene expression in brain using a herpes simplex virus vector. Gene Ther 1998; 5: 491-496.
83. Wang S, Petravicz J, Breakfield X. Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. Mol Ther 2003; 7: 790-800.
84. Haberman RP, McCown TJ, Samulski RJ. Inducible long-term gene expression in brain with adeno-associated virus gene transfer. Gene Ther 1998; 5: 1604-1611.
85. Fitzsimons HL, McKenzie JM, During MJ. Insulators coupled to a minimal bidirectional tet cassette for tight regulation of rAAV-mediated gene transfer in the mammalian brain. Gene Ther 2001; 8: 1675-1681.
86. Solera JA. Treatment of human brucellosis with netilmicin and doxycycline. Clin Infect Dis 1996; 22: 441-445.
87. Tenenbaum L, Lehtonen E, Monahan P. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther 2003; 3: 545-566.
88. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003; 9: 589-595.
89. Zhang Z, Miyoshi Y, Lapchak PA, et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 1997; 282: 1396-1401.